Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05904886 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 687
- Enrollment target
- 20
- Study locations
NCT05904886: Active Phase 3 study of Hepatocellular Carcinoma, sponsored by Hoffmann-La Roche.
NCT05904886 is a Phase 3 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 687 participants, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (172% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05904886, a Phase 3 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 687 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- OTHER Placebo
- DRUG Tiragolumab
Study Locations (20)
California
- UCSF Fresno at Community Cancer Institute - Clovis
- City of Hope Cancer Center - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
- Stanford Cancer Center - Palo Alto
- Va Palo Alto Health Care System - Palo Alto
- UCLA Cancer Center - Santa Monica
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) - Fort Myers
- Miami VA Healthcare System - Miami
- Florida Cancer Specialist, North Region - St. Petersburg
Michigan
- Henry Ford Health System - Detroit
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Arkansas
- Genesis Cancer Center - Hot Springs
Connecticut
- Hartford Healthcare Cancer Institute at Hartford Hospital - Hartford
District of Columbia
- MedStar Washington Hosp Center - Washington D.C.
Illinois
- University of Illinois - Chicago
Kentucky
- Norton Cancer Institute - Audubon - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 687 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 3 |
What the registry record for NCT05904886 still lists
NCT05904886 is an interventional study that assigns participants to a tested intervention. The registered 687 participants enrollment target is mid-sized for trials with a published cap, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (172% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT05904886 names 20 study sites across 11 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05904886 about?
NCT05904886 is a clinical study titled "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)". The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version ...
What is the current status of trial NCT05904886?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 687 participants. The study started on 2023-09-14. Estimated completion is 2026-09-01.
What conditions does trial NCT05904886 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05904886?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Placebo (OTHER), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT05904886?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05904886 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05904886's enrollment target sits among peer trials
687 20th of 145 higher than 126 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05750654 · 688 participants · NA
Effectiveness of Small Phlebotomy Tubes in Reducing Blood Transfusions in Adult Medical Intensive Care Unit and Intermediate Care Unit Patients With Anemia
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- NCT06618274 · 686 participants · NA
Effectiveness of Central Oncology Navigation and the Use of an ORN
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI